Table 1.

Prevalence of HLA–B27 in US adults ages 20–69 years, by selected characteristics, NHANES 2009 data^*

	Sample		Prevalence†
Selected characteristics	No. positive for HLA–B27	Total population	% (95% CI)	SE
Overall US prevalence	124	2,320	6.1 (4.6–8.2)	0.8
Sex
Male	53	1,123	5.8 (3.9–8.4)	1.0
Female	71	1,197	6.5 (4.7–8.9)	1
Race/ethnic group
Non-Hispanic white	79	1,021	7.5 (5.3–10.4)‡	1.2
Mexican American	27	622	4.6 (3.4–6.1)§	0.6
Non-Hispanic black	4	345	1.1 (0.4–3.1)¶	0.5
Age group
20–29 years	39	498	8.0 (4.6–13.4)	2.0
30–39 years	26	471	5.6 (3.4–9.2)	1.3
40–49 years	34	508	8.1 (5.8–11.2)	1.2
50–59 years	11	404	2.9 (1.4–5.8)¶	0.9
60–69 years	14	439	4.6 (1.9–10.7)¶	1.9

^*For race/ethnicity, only data for the major subgroups in the US are shown, which therefore do not sum to the overall sample size. All race/ethnicities are included in the overall prevalence estimates and in the prevalence estimates by sex and age. NHANES = National Health and Nutrition Examination Survey.

^†Estimates for sex and race/ethnicity are age-adjusted to the 2000 US civilian population using age groups 20–29 years, 30–39 years, 40–49 years, 50–59 years, and 60–69 years. The 95% confidence intervals (95% CIs) were constructed using the logit transformation (3).

^‡P < 0.01 versus all other race/ethnic groups combined.

^§P < 0.05 versus non-Hispanic white persons.

^¶Estimates do not meet criteria for statistical stability.